Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4222279

CC(C)CCNC(=O)C(Nc1ccc(C#N)cn1)c1ccccc1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 20/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4237396 0.88 EP300 (0.52) EP300
Trifluoroacetic Acid SCHEMBL4227766 0.81 MTTP (0.43) EP300
Trifluoroacetic Acid SCHEMBL4227412 0.79 HCRTR1 (0.45) EP300
Trifluoroacetic Acid SCHEMBL4232750 0.77 ALDH1A1 (0.43) EP300
Trifluoroacetic Acid SCHEMBL3607735 0.74 HCAR3 (0.43)
Trifluoroacetic Acid SCHEMBL4228165 0.73 IRAK4 (0.41) EP300
SCHEMBL4222280 0.71 CNR1 (0.36) EP300
SCHEMBL27305663 0.69 AR (0.55)
Trifluoroacetic Acid SCHEMBL3603250 0.68 DPP7 (0.49)
SCHEMBL1709554 0.68 EP300 (0.53) EP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2096104-A1 Organic diamines as mGluR7 modulators Novartis AG (CH) 2009-09-02 EP disclosed
US-20080242698-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242698-A1 Organic Compounds AOC1, OTC, ODC1 EP300 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.